194 related articles for article (PubMed ID: 18702822)
21. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Tubbs R; Barlow WE; Budd GT; Swain E; Porter P; Gown A; Yeh IT; Sledge G; Shapiro C; Ingle J; Haskell C; Albain KS; Livingston R; Hayes DF
J Clin Oncol; 2009 Aug; 27(24):3881-6. PubMed ID: 19620488
[TBL] [Abstract][Full Text] [Related]
22. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.
Zaczek AJ; Markiewicz A; Seroczynska B; Skokowski J; Jaskiewicz J; Pienkowski T; Olszewski WP; Szade J; Rhone P; Welnicka-Jaskiewicz M; Jassem J
Oncologist; 2012; 17(10):1246-55. PubMed ID: 22871798
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer.
Moelans CB; de Weger RA; van Blokland MT; van der Wall E; van Diest PJ
Mod Pathol; 2010 Jan; 23(1):62-70. PubMed ID: 19767729
[TBL] [Abstract][Full Text] [Related]
25. Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.
Chen JR; Chien HP; Chen KS; Hwang CC; Chen HY; Yeh KY; Hsieh TY; Chang LC; Hsu YC; Lu RJ; Hua CC
Medicine (Baltimore); 2017 Jan; 96(2):e5582. PubMed ID: 28079792
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.
Reinholz MM; Bruzek AK; Visscher DW; Lingle WL; Schroeder MJ; Perez EA; Jenkins RB
Lancet Oncol; 2009 Mar; 10(3):267-77. PubMed ID: 19261255
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Bramwell VH; Andrulis IL; Pritchard KI
J Natl Cancer Inst; 2009 May; 101(9):644-50. PubMed ID: 19401546
[TBL] [Abstract][Full Text] [Related]
28. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
[TBL] [Abstract][Full Text] [Related]
29. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
[TBL] [Abstract][Full Text] [Related]
30. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
[TBL] [Abstract][Full Text] [Related]
31. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
[TBL] [Abstract][Full Text] [Related]
32. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
Rody A; Karn T; Ruckhäberle E; Müller V; Gehrmann M; Solbach C; Ahr A; Gätje R; Holtrich U; Kaufmann M
Breast Cancer Res Treat; 2009 Feb; 113(3):457-66. PubMed ID: 18340528
[TBL] [Abstract][Full Text] [Related]
33. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas.
Bofin AM; Ytterhus B; Hagmar BM
Cytopathology; 2003 Dec; 14(6):314-9. PubMed ID: 14632728
[TBL] [Abstract][Full Text] [Related]
34. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
35. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
36. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
Meng H; Chen R; Li W; Xu L; Xu L
Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
[TBL] [Abstract][Full Text] [Related]
37. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
[TBL] [Abstract][Full Text] [Related]
38. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
[TBL] [Abstract][Full Text] [Related]
39. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.
Fritz P; Cabrera CM; Dippon J; Gerteis A; Simon W; Aulitzky WE; van der Kuip H
Breast Cancer Res; 2005; 7(3):R374-84. PubMed ID: 15987433
[TBL] [Abstract][Full Text] [Related]
40. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays.
Callagy G; Pharoah P; Chin SF; Sangan T; Daigo Y; Jackson L; Caldas C
J Pathol; 2005 Feb; 205(3):388-96. PubMed ID: 15682439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
